贝伐单抗治疗卵巢癌
Bevacizumab in the treatment of ovarian cancer.
作者信息
Eskander Ramez N, Randall Leslie M
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA;
出版信息
Biologics. 2011;5:1-5. doi: 10.2147/BTT.S13071. Epub 2011 Jan 11.
Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens. Since that time however, overall survival has been stable. Given the above, an emphasis has been placed on exploring alternative therapeutics. Recent research efforts have improved our understanding of the molecular biology of ovarian cancer and novel targeted treatment strategies have emerged. The most studied of these agents has been the monoclonal anti-vascular endothelial growth factor antibody bevacizumab. The purpose of this review is to discuss management issues related to the treatment of ovarian cancer, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, its potential benefits, and reported adverse events.
尽管在手术细胞减灭术和细胞毒性化疗方面取得了进展，但卵巢癌仍然是妇科恶性肿瘤女性死亡的主要原因。随着铂类和紫杉烷类辅助化疗方案的发现，我们对卵巢癌治疗的认识发生了革命性变化。然而，自那时以来，总体生存率一直保持稳定。鉴于上述情况，人们将重点放在探索替代疗法上。最近的研究工作增进了我们对卵巢癌分子生物学的理解，新的靶向治疗策略也应运而生。其中研究最多的药物是抗血管内皮生长因子单克隆抗体贝伐单抗。本综述的目的是讨论与卵巢癌治疗相关的管理问题，重点是贝伐单抗的应用，总结适用的临床试验、其潜在益处以及报告的不良事件。
Zotero 插件